Search results for "GFA"

showing 2 items of 12 documents

2015

The pathogenesis of glaucoma, a common neurodegenerative disease, involves an immunologic component. Changes in the natural autoantibody profile of glaucoma patients were detected, showing not only up-regulated but also down-regulated immunoreactivities. In recent studies we were able to demonstrate that the antibody changes have a large influence on protein profiles of neuroretinal cells. Furthermore we could demonstrate neuroprotective potential of one of the down-regulated antibodies (γ-synuclein antibody). Anti-GFAP antibody is another antibody found down-regulated in glaucoma patients. Since GFAP expression is intensified in glaucomatous retina, the aim of this study was to detect the …

PharmacologyRetinaGlial fibrillary acidic proteinbiologymedicine.diagnostic_testAutoantibodyActin cytoskeletonGFAP stainMolecular biologyNeuroprotectionmedicine.anatomical_structureWestern blotbiology.proteinmedicineMolecular Medicinesense organsAntibodyJournal of Pharmacological Sciences
researchProduct

GABA-B receptora agonista baklofēna ļoti mazo devu ietekme uz neiroiekaisuma proteīnu ekspresiju netransgēnajā AD-tipa žurku modelī

2017

Šī darba mērķis bija noteikt GABAB receptora agonista baklofēna ļoti mazo devu (0,025 un 0,05 mg/kg) efektus uz neiroiekaisumu (GFAP) un acetilholīna šķelšanu (AChE) streptozocīna (STZ) icv AD-tipa žurku modelī. Rezultāti rāda, ka: a) STZ ievadīšana izraisīja statistiski ticamu GFAP un AChE blīvuma palielinājumu smadzenēs, norādot uz neiroiekaisumu un palielinātu acetilholīna daudzuma samazināšanos b) Abās devās baklofēns aizsargāja pret STZ inducēto neiroiekaisumu, būtiski samazinot GFAP blīvumu līdz kontroles grupas rādītājiem; c) Baklofēna ievadīšana normalizēja arī STZ ievadīšanas rezultātā palielinātu acetilholīna šķelšanu. Iegūti dati liecina, ka GABAB agonista baklofēna ļoti mazās de…

baklofēnsGFAPAlcheimera slimībaAChEFarmācijaneiroiekaisums
researchProduct